ACRS · Aclaris Therapeutics Inc
United States · RS rating 28 · As of 2026-10-14
| Price | 3.38 USD |
|---|---|
| 1-day change | -2.6% |
| RS rating (overall / 1M / 3M / 12M) | 28 / 4 / 9 / 93 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 32 / 35 / 34 |
| Industry group (rank) | Medical-Generic Drugs (94) |
| EPS growth Q/Q | -33.3% |
| Sales growth Q/Q | -60.8% |
| Distance from 52-week high | +48.3% |
| Market cap (USD) | $635.5M |